Genprex Adds Clinical Trial Site for Acclaim-1 and Acclaim-3 Lung Cancer Clinical Trials

Core Insights - Genprex, Inc. has added Gabrail Cancer Center in Canton, Ohio, as a new clinical trial site for its Acclaim-1 and Acclaim-3 clinical trials studying Reqorsa® Gene Therapy for lung cancer [1][2] - The company aims to expand its reach and expedite patient enrollment in these trials, which have received FDA Fast Track Designation [1][4] Acclaim-1 Clinical Trial - Acclaim-1 is a Phase 1/2 clinical trial evaluating the combination of Reqorsa and AstraZeneca's Tagrisso® for late-stage non-small cell lung cancer (NSCLC) patients with activating EGFR mutations [2][4] - The Phase 1 portion showed that Reqorsa was well tolerated with no dose-limiting toxicities, and early signs of efficacy were observed [3][4] - The trial plans to enroll approximately 33 patients, with an interim analysis expected after treating 19 patients, anticipated to be completed in the first half of 2026 [4] Acclaim-3 Clinical Trial - Acclaim-3 is a Phase 1/2 clinical trial evaluating the combination of Reqorsa and Genentech's Tecentriq® as maintenance therapy for extensive stage small cell lung cancer (ES-SCLC) [5][7] - The Phase 2 expansion is expected to enroll around 50 patients, with the primary endpoint being the 18-week progression-free survival rate [7] - An interim analysis will be conducted after the 25th patient reaches 18 weeks of follow-up, with completion of enrollment for this analysis also expected in the first half of 2026 [7] Company Overview - Genprex, Inc. is focused on developing gene therapies for cancer and diabetes, utilizing its Oncoprex® Delivery System to administer disease-fighting genes [8][9] - The company's lead product candidate, Reqorsa, is being evaluated in two clinical trials for NSCLC and SCLC, both of which have received FDA Fast Track Designation [9]